Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2010 / Cilt: 50 - Sayı: 3

Evaluation of macroalbuminuria regression in type 2 diabetic macroalbuminuric patients

Tip 2 diyabetik makroalbuminürik hastalarda makroalbüminüri regresyonun değerlendirilmesi

Pages
111–116
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Patients has divided into two groups according to the degree of UAE:

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Diabetic nephropathy is the leading cause of end-stage renal disease.
📊
Key Findings & Data:In this study the incidence and predictors of regression of macroalbuminuria in patients with type 2 diabetes overt diabetic nephropathy were investigated in our routine clinical practice.
💡
Conclusion & Impact:Patients has divided into two groups according to the degree of UAE:
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: Diabetic nephropathy is the leading cause of end-stage renal disease. Intensive multifactorial treatments can slow the progression of disease and even reverse it in some instances. In this study the incidence and predictors of regression of macroalbuminuria in patients with type 2 diabetes overt diabetic nephropathy were investigated in our routine clinical practice. Patients and methods: Thirty seven diabetic patients with persistent macroalbuminuria (urinary albumin excretion, UAE ?300 mg/24 hrs) who followed for 3-6 years (mean: 4.1±1.0 years) in our clinic were included; patient’s data was obtained from hospital records. Patients has divided into two groups according to the degree of UAE:

Özet

Amaç: Diyabetik nefropati, son dönem böbrek yetmezli¤inin en önemli nedenlerinden biridir. Yo- ¤un ve çok yönlü tedavi yaklaşımları ile hastalı- ¤ın ilerlemesi yavaşlatılabilir ve hatta bazı durumlarda geriletilebilir. Çalışmamızda ola¤an klinik prati¤imizde izledi¤imiz aşikar diyabetik nefropatisi bulunan tip 2 diyabetik hastalarda makroalbüminüri regresyonunun insidansı ve prediktörleri araştırılmıştır. Hastalar ve yöntem: Klini¤imizde 3-6 yıl süre ile (ortalama:4.1±1.0 yıl) Tip 2 diyabetes mellitus tanısı ile takipli, kalıcı makroalbüminürisi (idrar albümin atılımı (İAA) ?300 mg/24 saat) bulunan 37 erişkin hasta, hasta bilgileri hastane kayıtları ndan elde edilmek suretiyle çalışmaya dahil edilmiştir. Takip sonrasında hastalar, İAA’nın 300 mg/24 saat’in altına inmesine veya 300 mg/24 saat ve üzerinde sebat etmesine göre iki gruba ayrılmış, her iki grubun laboratuvar ve klinik parametreleri karşılaştırılmıştır. Bulgular: Çalışmaya katılanların yaş ortalaması 62,6 ± 8,4 yıl, diyabet süresi 12,0 ±7,8 yıldı. Tüm hastalar insülin tedavisi almaktaydı. İAA 14 hastada (%38) 300 mg/24 saat’in altına geriledi. İAA’da gerileme görülen hastaların albüminüri seviyelerinde %71’lik azalma, makroalbüminürisi devam eden hastaların albüminüri seviyelerinde %228’lik artış saptandı. Kreatinin klirensi her iki grupta da benzer oranda düşüş gösterdi (sırasıyla: %22 ve %17; p=0,835). İdrar albümin atılımındaki yüzde de¤işim, bazal ve takip sonrası HbA1c (sırasıyla: r =0,37 p=0,023 ve r =0,58 p

🔖

Cite This Article

SERTBAŞ, Y., DAYAN, A., BULGURLU, S. S., ABANONU, B. G., DEMİRTUNÇ, R. (2022). Evaluation of macroalbuminuria regression in type 2 diabetic macroalbuminuric patients. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 50 - Sayı: 3, 111–116. https://ajindex.com/articles/535459

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Standards of medical care in diabetes—2009. Diabetes Care 2009;32 Suppl 1:S13-61
  2. Araki S, Haneda M, Koya D, Kashiwagi A, Uzu T, Kikkawa R. Clinical impact of reducing microalbuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008;82 Suppl 1:S54-8
  3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9
  4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60
  5. Araki S, Haneda M, Sugimoto T, et al. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005;54:2983-7
  6. Gaede P, Tarnow L, Vedel P, Parving HH, Pedersen O. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004;19:2784-8
  7. Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005;45:281- 7. 8. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20
  8. Rossing K, Christensen PK, Hovind P, Parving HH. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia 2005;48:2241-7
  9. Araki S, Haneda M, Koya D, et al. Reduction in microalbuminuria as an integrated indicator for renal and cardiovascular risk reduction in patients with type 2 diabetes. Diabetes 2007;56:1727-30
  10. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
  11. Levin SR, Coburn JW, Abraira C, et al. Effect of intensive glycemic control on microalbuminuria in type 2 diabetes. Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type 2 Diabetes Feasibility Trial Investigators. Diabetes Care 2000;23:1478-85
  12. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75. 1